Ticker: NUVL

GSK's stock dipped over 2% following its $10.6 billion acquisition of US biotech firm Nuvalent, centered on promising lung cancer treatments with FDA breakthrough designations. The deal carries a notable premium and plans to fuel revenue by 2027.

Nuvalent, Inc. (NASDAQ: NUVL) is navigating a critical phase as a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Despite the potential of its lead product candidates, the company is grappling with significant financial challenges and operational hurd...